 |
 |
 |
 |
 |
 |
 |
 |
E. William Radany, Ph.D.
has over 25 years experience in the biotechnology industry. Prior to joining CODA, he was President and CEO of High Throughput Genomics, Inc., a provider of novel array-based gene expression assay technology for the life science industry. Dr. Radany was also previously President of Biacore, founder and CEO of NeoGenex and has held executive positions at Xencor, Caliper Technologies and Stratagene.
Neal Bhadkamkar, Ph.D.
is co-founder and Managing Partner of Monitor Ventures, the early stage venture capital affiliate of The Monitor Group. Before co-founding Monitor Ventures, Neal had a successful career in technology commercialization at Zowie Intertainment and Interval Research, Paul Allen's research and commercialization company. Neal serves on the board of two other private companies: Nanostellar Inc., a Stanford University spinout developing model-based design tools for advanced nano-materials, and 3DMatrix Inc., an MIT spinout commercializing self-assembling synthetic peptide scaffolds for a variety of life science applications.
Robert Engler, M.D.
is Professor of Medicine, Emeritus, UCSD, in Cardiology. He was Professor of Medicine at UCSD from 1975 to 2001. His research discoveries include the role of white blood cells in reperfusion injury and capillary no-reflow, adenosine protection of the myocardium, and cardiomyocyte apoptosis. He has authored 19 book chapters and over 80 scientific publications. He was a founder of Gensia (currently Sicor), Collateral Therapeutics (sold to Schering, AG), and the Veterans Medical Research Foundation (VMRF). He served as President and Chairman of VMRF from 1992-2002.
J. Randolph Lathrop
is currently a private investor. Mr. Lathrop was formerly a Managing Director in GE Capital's Private Equity and Capital Markets divisions for ten years, and for three years until March 2003 he was President of a $200 million dollar private equity fund for Japanese investments. The fund, based in Tokyo, Japan, was 50% owned by GE Capital. He has over twenty years experience in international banking and investments, principally in the areas of Capital Markets and Financial Advisory services. He received a BA in Biology from Reed College and completed coursework for his Masters in International Business and Finance at the Fletcher School, Tufts University.
Chad Waite
has more than 25 years of experience in both the management and investment sides of emerging growth companies. In 1987, he left his post as General Partner at Hambrecht & Quist Venture Partners to join OVP Venture Partners. Prior to that, he was in marketing and sales management at Cobe Laboratories, Inc. in its cardiovascular medical products division. Mr. Waite earned an
AB in History from Kenyon College and an MBA from Harvard University.
Drew Senyei, M.D.
is a managing director at Enterprise Partners where he leads the life science practice. Drew focuses on investments in pharmaceuticals, biopharmaceuticals, diagnostics, medical devices and consumer healthcare. Drew has served on over 25 public and private boards including Adeza Biomedical, NuVasive, Corixa Corp., Ligand Pharmaceuticals, Nanogen, Inc., and Discovery Partners. He currently sits on the boards of Enterprise portfolio companies including: Anaborex, Ascenta Therapeutics, Celladon, Ceula, Complete Genomics, Genoptix, Ophthonix, and TargeGen.
Richard D. Murdock
has over 30 years experience in executive management, fund raising, marketing and business development in the biotech therapeutics and medical device industries. His tenure as CEO includes Sangstat Medical Corporation (aquired by Genzyme), Kyphon and Cellpro, Inc. At Baxter Heathcare, Rick ran the Fenwal Automation Business Unit and later The Fenwal Europe Business Unite. Rick has additional marketing and product development experience in several start-up companies including Hemascience Laboratories, Cytogen, and Haemonetics Corporation.